The development of precision radiopharmaceuticals in oncology, using camelid single-domain antibodies, labeled with radioisotopes, allows radiotherapy to be directed to its specific target, the cancer cell, and deliver the radioactive load in a highly selective manner to the tumor, preventing the radiation from reaching the rest of the body.
Dámaso Molero, Chief Executive Officer of 3P Biopharmaceuticals commented: “The alliance with Precirix is an exciting new venture for 3P, where, once again, innovation and technology come together making it possible to develop novel drugs against cancer. We look forward to being part of the Precirix journey.”
“This collaboration marks an important step in advancing our second pipeline program towards the clinic. We are confident 3P is the right partner for the manufacturing of our highly selective single domain antibody”, said Ruth Devenyns, Chief Executive Officer of Precirix.
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology, and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.
View the full press release here
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Investigadores del Cima Universidad de Navarra constatan que la combin...
